Brief: EQL Pharma Sets New Financial Targets
07/03/2025 07:39
March 7 (Reuters) - EQL Pharma AB EQL.ST: NEW FINANCIAL TARGETS FOR THE PERIOD 2024/25 - 2028/29 TARGET IS TO INCREASE SALES AT AN ANNUAL GROWTH RATE OF 30% (CAGR), STARTING WITH FULL YEAR 2024/25 AND ENDING FULL YEAR 2028/29 IN CONNECTION WITH ANY ACQUISITIONS, PRIMARY SOURCES OF FUNDING WILL BE EXISTING CASH ALONGSIDE POTENTIAL NEW DEBT TARGET TO REDUCE NET LEVERAGE (NET DEBT/PRO-FORMA ADJUSTED EBITDA) TO BELOW 2.5X. EBITDA MARGIN TARGET FOR PERIOD IS 25% UNDER FIVE-YEAR PLAN, REVENUE GROWTH WILL BE PRIORITIZED OVER HIGHER EBITDA MARGIN TO MAXIMIZE LONG-TERM SHAREHOLDER VALUE TAKING INTO CONSIDERATION A MAINTAINED HEALTHY MARGIN Source text: ID:nWkr5HrZY3 Further company coverage: EQL.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))